EFX的耐受性良好，最常见的不良事件是1级或2级胃肠道事件（腹泻、恶心和食欲增加）。 1例接受EFX治疗的患者因恶心而停药，1例在撤回同意后停药。

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Equifax Inc (NYSE:EFX) showcases robust revenue growth and operational efficiency in its latest quarterly report. Strategic positioning in credit information services and workforce solutions ...

Investing.com - TD Cowen 对 Akero Therapeutics (NASDAQ: AKRO) 启动覆盖，给予买入评级，目标价为 76.00 美元。根据 InvestingPro 数据，这与分析师的强烈共识一致，目标价范围在每股 60 美元至 109 美元之间。该公司股票表现出令人印象深刻的增长势头，过去一年回报率达 92%。

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...